CD8A and cancer: It would also be interesting to determine whether this Nrp-1+PD-1high CD8+ TIL subset is influenced by PD-1 blockade in human cancer samples and to validate Nrp-1 expression on TIL as a predictive biomarker for response to cancer immunotherapy.